With the rumor mill once again trying to match up Gilead Sciences Inc. with PARP inhibitor specialist Tesaro Inc., analysts at Datamonitor Healthcare's PharmaVitae team have been weighing up acquisition targets for the US biotech major that may make more sense.
In a new report evaluating potential takeover targets for the bigger players in the sector, PharmaVitae has highlighted Gilead as one of the firms likely to do more deals to further plug revenue declines in the hepatitis C market